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Astrocytes are the most abundant cell type in the human 
brain and are important regulators of several critical cel-
lular functions, including synaptic transmission. Although 
astrocytes are known to play a central role in the etiology 
and pathophysiology of schizophrenia, little is known 
about their potential involvement in clinical response to the 
antipsychotic clozapine. Moreover, astrocytes display a re-
markable degree of morphological diversity, but the poten-
tial contribution of astrocytic subtypes to disease biology 
and drug response has received little attention. Here, we 
used state-of-the-art human induced pluripotent stem cell 
(hiPSC) technology to derive a morphological subtype of 
astrocytes from healthy individuals and individuals with 
schizophrenia, including responders and nonresponders 
to clozapine. Using functional assays and transcriptional 
profiling, we identified a distinct gene expression signature 
highly specific to schizophrenia as shown by disease asso-
ciation analysis of more than 10 000 diseases. We further 
found reduced levels of both glutamate and the NMDA 
receptor coagonist d-serine in subtype astrocytes derived 
from schizophrenia patients, and that exposure to cloza-
pine only rescued this deficiency in cells from clozapine 
responders, providing further evidence that d-serine in par-
ticular, and NMDA receptor-mediated glutamatergic neu-
rotransmission in general, could play an important role in 
disease pathophysiology and clozapine action. Our study 
represents a first attempt to explore the potential contri-
bution of astrocyte diversity to schizophrenia pathophysi-
ology using a human cellular model. Our findings suggest 
that specialized subtypes of astrocytes could be important 
modulators of disease pathophysiology and clinical drug 
response, and warrant further investigations.
Key words:  hiPSC/astrocyte diversity/transcription/glut
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Introduction
Astrocytes are ubiquitous cells in the central nervous 
system (CNS). Previously viewed as a passive and homog-
enous cell population whose main function was to pro-
vide structural support for neurons, these glial cells have 
recently emerged as an integral constituent of the CNS, 
where they actively participate in a variety of biological 
processes which are vital for proper brain functioning, 
including synaptogenesis and modulation of NMDA 
receptor-mediated glutamatergic neurotransmission.1 
Paralleling the increasingly popular glutamate hypoth-
esis of schizophrenia (SCZ),2 mounting evidence from 
postmortem, brain imaging, and genetic studies suggests 
that astrocytes play a critical role in the pathophysiology 
of SCZ.3,4 However, the precise molecular mechanisms 
underlying this astrocytic contribution to SCZ biology 
remain poorly understood, partly due to the inaccessi-
bility of human CNS tissue and the lack of appropriate 
animal and cellular models. Moreover, astrocytes display 
a remarkable degree of morphological, regional, and cel-
lular diversity,5 and although at least five distinct popu-
lations have been described in the human brain,6,7 very 
little is known about their molecular characterization. 
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Most functional and molecular studies published in re-
cent years have employed rodent models,5,8,9 which may 
not fully recapitulate human astrocyte heterogeneity as 
substantial species differences exist.7 Additionally, dif-
ferent astrocytic subtypes may mediate distinct patho-
physiological processes in uniquely human disorders, but 
this emerging area of astrocyte biology research remains 
unexplored.9 Recent method developments in human 
induced pluripotent stem cells (hiPSCs) biology have 
provided a feasible platform for the elucidation of cel-
lular and molecular anomalies in SCZ.10 Here, we study 
an hiPSC-derived morphological subtype of astrocytes 
generated from healthy individuals and individuals with 
SCZ, including patients responsive and nonresponsive 
to the antipsychotic clozapine (CLZ), and explore the 




A schematic of the overall design of the study can be 
found in supplementary figure 1. In total, morphological 
subtype astrocytes were generated from two healthy con-
trol (HC) and six schizophrenia (SCZ) hiPSC lines. To 
compare the transcriptional profiles of subtype astrocytes 
to classical astrocytes, these two cell types were derived 
from one of the HC lines and differentiated for 180 days, 
using three replicates of a single clone from each group 
of astrocytes for RNA-sequencing (RNA-seq) analysis. 
In addition, subtype astrocytes were generated from a 
human embryonic stem cell (hESC) line (CCTL14)11 to 
compare its differentiation propensity to that of hiPSCs 
using immunocytochemistry (ICC). The subtypes astro-
cytes derived from HC and SCZ hiPSC lines for RNA-
seq analysis were differentiated for 200 days.
Recruitment of SCZ Patients and Determination of 
CLZ Response
Patients were recruited through psychiatric units in Brno, 
Czech Republic. The main inclusion criteria were: con-
firmed SCZ diagnosis, prior or current treatment with 
CLZ, male sex, age between 20 and 60 years, and signed 
informed consent. Patients with another psychiatric dis-
order, somatic disorder affecting brain function, or IQ 
< 70 were excluded. Supplementary table 1 summarizes 
the demographic, clinical, and CLZ response charac-
teristics of all patient donors. Sources of data for diag-
nosis and determination of CLZ response status were 
medical records and an interview with a structure anal-
ogous to the Comprehensive Assessment of Symptoms 
and History (CASH) structured interview.12 In addition, 
two board-certified psychiatrists verified the diagnosis 
and assessed symptoms at the time of the recruitment 
using the Mini-International Neuropsychiatric Interview 
(MINI) structured interview.13 CLZ response status was 
determined on the basis of an initial evaluation of the 
medication used at the time of recruitment and a subse-
quent analysis of the medical records. CLZ responders 
(CLZ-R) had to (1) be treated with only CLZ at the initial 
assessment, and (2) show either full or partial but suffi-
cient effect of CLZ on positive and negative symptoms. 
Patients were considered CLZ nonresponders (CLZ-NR) 
if  (1) they were treated with any other antipsychotic alone 
or in combination with CLZ at the initial assessment, and 
(2) showed either no effect of CLZ or its combination 
with other medications, or experienced relapse of the 
symptoms during the CLZ treatment necessitating acute 
treatment with other drugs. A detailed description of the 
clinical procedures can be found in the online supplemen-
tary information.
Generation of hiPSC Lines and Derivation of Subtype 
Astrocytes
The hiPSC lines were generated from human dermal 
fibroblasts obtained from the recruited participants 
using the CytoTune-iPS 2.0 Sendai Reprogramming Kit 
(Invitrogen). To generate subtype astrocytes, hESCs were 
plated onto Matrigel-coated plates at 1000 cells/cm2 in the 
chemically defined conditional medium, whereas hiPSC 
lines were plated onto Matrigel-coated plates in clumps 
by manual cut-outs or aided with UltraPure EDTA 
(Invitrogen, 15575020)  in Essential 8 Medium (Gibco, 
A1517001) according to our previous studies.14,15 For 
RNA-seq analysis and d-serine and glutamate measure-
ments, subtype astrocytes were enriched at 90–120 days 
of differentiation by manually cutting out the cell colo-
nies and growing them in separate Matrigel-coated plates 
until 180 or 200 days of differentiation.
Functional Assays
The subtype astrocytes derived from one of the HC hiPSC 
lines were prepared for calcium imaging as described pre-
viously.14,15 Glutamate concentrations were measured 
using an ELISA assay (Abcam, ab83389). To measure 
d-serine, cell samples were treated with and without 1 μM 
CLZ after 166 days of differentiation for 2 weeks, fixed 
immediately on day 180, and stained with d-serine anti-
body (Abcam, ab6472) the next day. ICC was performed 
as described previously.14,15 The stained cells were exam-
ined using a confocal microscope (Zeiss LSM 700).
RNA Sequencing and Data Processing
Total RNA was extracted from the astrocyte samples 
using the RNeasy Plus Mini Kit (Qiagen). Sequencing li-
braries were prepared with the TruSeq Stranded mRNA 
kit (Illumina) and sequenced on an Illumina HiSeq 4000 
platform at an average depth of 50 million reads per 
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of 350  bp. Raw sequencing reads were quality assessed 
with FastQC (Babraham Institute) and further processed 
with Trimmomatic V0.32.16 Hisat217 was then used to first 
build a transcriptome index based on Ensembl annota-
tions, and then to map the trimmed reads to the human 
GRCh38 reference genome. To quantify gene expression 
levels, mapped reads were summarized at the gene level 
using featureCounts18 guided by Ensembl annotations.
Statistical Analyses
All differential expression (DE) analyses were per-
formed using DESeq2.19 A gene was considered signifi-
cant if  the FDR was <0.1. Over-representation tests of 
GO terms (biological processes) were conducted with 
clusterProfiler,20 while disease association analysis was 
performed with the R package disgenet2r.21 In both cases, 
FDR <0.05 was used as the threshold to determine signif-
icant enrichment. A detailed description of the materials 
and methods used in this study can be found in the online 
supplementary information.
Results
Derivation and Molecular Characterization of Subtype 
Astrocytes
To study the transcriptional profiles of hiPSC-derived 
subtype astrocytes and their alterations in SCZ and 
CLZ response, we generated astrocytes from a control 
hiPSC line and a human embryonic stem cell (hESC) 
line using a modified version of our previously pub-
lished neural differentiation protocol14 (figure  1A, sup-
plementary figure  1). After ~45  days of differentiation, 
a morphological subpopulation of GFAP and S100B-
positive cells started to appear and were subsequently 
enriched by physical translocation (figure  1A). This as-
trocytic subpopulation was characterized by a distinc-
tive morphology which was elongated and unbranched 
(figure  1B), exhibiting structural similarities to the 
primate-specific interlaminar astrocytes residing in the 
upper cortical layers.22 To our knowledge, this morpho-
logical subpopulation of astrocytes has not been assessed 
previously in vitro. The astrocytes exhibited structural 
diversity along their single process, which displayed a 
predominantly oblong morphology, but could also be 
tortuous and to a lesser extent varicose (figure 1C). The 
tail-ends were also morphologically diverse, typically 
fanning out in brush-like structures of various shapes 
(figure 1D). As astrocytes are known to be involved in the 
modulation of NMDA receptor-mediated glutamatergic 
neurotransmission, both by responding to, and the po-
tential release of, neurotransmitters,23 we used calcium 
imaging and immunocytochemistry (ICC) to examine the 
presence of glutamate-evoked calcium transients and to 
assess protein expression of d-serine in the derived astro-
cytes, respectively. We found that exposure to glutamate 
elicited pulsatile and synchronous calcium transients 
(supplementary movie 1), and that d-serine was ex-
pressed and distributed throughout the cell, including the 
soma, process, and tail-ends (supplementary figure  2), 
suggesting that these subtype astrocytes may respond to 
glutamatergic signaling in the brain.
Transcriptional Profiling of Subtype Astrocytes
As structural heterogeneity implies variability in the un-
derlying patterns of gene expression, RNA sequencing 
(RNA-seq) was used to compare the transcriptional 
profiles of the derived subtype astrocytes with those of 
“classical” astrocytes displaying a typical branched mor-
phology (figure 1E). Both subtype and classical astrocytes 
were derived from the same hiPSC line (three replicates 
each), and global gene expression was assessed after 
180  days of differentiation (figure  1A). Principal com-
ponent analysis (PCA) showed a complete separation 
on cell type across the first two components, explaining 
98% of the variation in gene expression (figure  1F). 
Computational deconvolution of four major brain cell 
types suggested that some of the observed variation may 
be attributed to cell type composition, as two cell types 
(astrocytes and neurons) were found to be present in sig-
nificantly different abundances across the two astrocytic 
groups (figure 1G, supplementary table 2). Consequently, 
the effects of cell type composition were corrected for in 
downstream analyses. Differential expression (DE) anal-
ysis identified 1720 (11%) genes with genome-wide sig-
nificance (FDR < 0.1), of which 1050 were upregulated 
and 670 were downregulated in subtype astrocytes com-
pared to classical astrocytes (figure  1H, supplementary 
table 3). The upregulated DE genes were enriched for sev-
eral biological processes (GO terms) related to synaptic 
transmission (figure  1I and J, supplementary table  4), 
suggesting a potential role of the derived astrocytes in 
synapse-related processes. As no specific markers for dif-
ferent subpopulations of human astrocytes have yet been 
validated,5 we compared the transcriptional profiles of 
the derived astrocytes with the profiles of primary brain 
cells isolated from human cortical samples24 to assess 
their similarities. Hierarchical clustering and correlation 
analysis showed that our derived astrocytes both clus-
tered together and correlated strongly with human adult 
astrocytes, suggesting that they bear transcriptional re-
semblance to the astrocytes found in vivo (supplementary 
figure 3).
Subtype Astrocytes from SCZ Patients Display 
Disease-Specific Signatures
Specific subsets of human astrocytes may contribute to neu-
ropsychiatric disorders, but this emerging area of research 
is in its infancy and little is known about the underlying 
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Fig. 1. Derivation and characterization of astrocytic subtype population. (A) Outline of the neural differentiation protocol used 
to derive subtype astrocytes from a hESC and a hiPSC cell line (hPSCs). RNA-seq for comparison between classical and subtype 
astrocytes was performed on 180 days old hiPSCs only. (B) Differentiation of hESC and hiPSC-derived subtype astrocytes from day 
40 to 180. Scale bar: 50 μm. (C) Morphological diversity of derived subtype astrocytes at day 100 of differentiation. Scale bar: 20 μm. 
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landscape of subtype astrocytes in the context of SCZ, 
the same neural differentiation protocol was employed to 
derive subtype astrocytes from two healthy controls (HC) 
and six SCZ patients, including three CLZ responders 
(CLZ-R), and three nonresponders (CLZ-NR) (figure 2A, 
supplementary figure  1). These astrocytes were differenti-
ated for 20 additional days (200 days in total) in order to 
increase the purity of the cell cultures. All samples stained 
positive for the pluripotency markers OCT4, TRA-1–81, 
NANOG, and SSEA4 at the iPSC stage (figure 2B), as well 
as the astrocytic marker GFAP at the mature astrocyte stage 
(figure  2C). ELISA measurements of intracellular gluta-
mate concentrations revealed significantly reduced gluta-
mate levels in SCZ astrocytes compared to HCs (figure 2D). 
A  corresponding decrease in mRNA levels of the major 
glutamate transporter genes SLC1A2 and SLC1A3 was not 
found (supplementary figure 4), suggesting that the reduc-
tion in intracellular glutamate was likely driven by dysfunc-
tional de novo synthesis25 rather than decreased glutamate 
uptake from the extracellular space. Clustering of samples 
by PCA showed a clear separation on diagnosis (figure 2E), 
and although the effects of cell type composition may ex-
plain some of this variation, no significant difference in 
cell type abundances was found (figure 2F, supplementary 
table  5). In total, 504 genes were differentially expressed 
(FDR < 0.1) across the two diagnostic groups, 211 of 
these were upregulated and 293 were downregulated in 
SCZ astrocytes (Fig. 2G, Suppl. Table 6). The upregulated 
genes were enriched for several immune-related biological 
processes, which is in line with known inflammatory dis-
turbances in SCZ26 and the important role of astrocytes in 
regulating neuroinflammation.27 The downregulated genes 
were enriched for multiple GO terms related to synaptic 
function, indicating a disrupted regulation of synaptic neu-
rotransmission or altered astroglial sensitivity to synaptic 
signals (figure 2H and I, supplementary table 7). We per-
formed additional DE and pathway analyses on three SCZ 
and three HC astrocytes from our previous study28 which 
used a nearly identical differentiation protocol to generate 
classical astrocytes from hiPSC cells. We identified fewer 
DE genes compared to the present study, and the genes 
were mostly enriched for ribosomal and mitochondrial 
functions (supplementary figure 5), which indicates that our 
findings are related to astrocytic diversity rather than repre-
senting general SCZ mechanisms present in all astrocytes. 
Importantly, disease association analysis showed SCZ as the 
most enriched disease term among a curated set of 10,370 
diseases (figure  2J, supplementary table  8, supplementary 
figure 6), strongly supporting the SCZ-specific nature of the 
transcriptional signature identified.
CLZ Rescues Deficient D-Serine Levels in Subtype 
Astrocytes Derived from Responders
Clozapine (CLZ) is the primary antipsychotic used in 
treatment-resistant SCZ, and 60%–70% of patients 
treated with CLZ show a response.29 Although CLZ is 
primarily a serotonin/dopamine modulator, it has been 
proposed that it could also induce its therapeutic effects 
through glutamatergic regulation.30 However, studies have 
shown conflicting evidence as to the precise role played 
by the NMDA receptor coagonist d-serine.31 Using ICC, 
we found a significant and CLZ response-independent 
decrease in d-serine levels in SCZ astrocytes relative to 
HCs. Intriguingly, exposing the cell cultures to CLZ res-
cued the d-serine deficiency in CLZ responders but not 
in nonresponders (figure  3A, supplementary figure  7), 
indicating that d-serine could be an important mediator 
of CLZ response in the brain. To further elucidate the 
molecular mechanisms of CLZ response in human astro-
cytes, we conducted both a targeted (72 genes of interest 
related to glutamate and d-serine-metabolism and trans-
port) and a global DE analysis. The targeted analysis 
identified 3 genes (SYT1, BDNF, and KCNJ10) with dif-
ferential expression across CLZ-R and CLZ-NR groups 
(figure 3B, supplementary table 9), with the strongest as-
sociation (P = .007) seen for SYT1, considered the master 
switch responsible for neurotransmitter release.32 In the 
global analysis, four genes (SERPINA5, LNX1, TMCC3, 
and ADAMTS9) were significantly associated (FDR < 
0.1) with CLZ response (figure 3C and D, supplementary 
table  10). Interestingly, SERPINA5 encodes a member 
of the serine protease inhibitor family of proteins, or 
serpins, which has been implicated in synaptic plasticity 
and memory formation.33 Heatmap analysis showed no 
overlap in expression levels of the four genes between the 
two CLZ response groups, indicating a strong correlation 
with response status (figure 3E).
Discussion
In the present study, we derived a morphological 
subpopulation of hiPSC astrocytes and examined its 
gene expression profile with respect to SCZ pathology 
and CLZ response, with a particular focus on genes and 
images of GFAP-positive classical and subtype astrocytes derived from control hiPSC lines and used for RNA-seq analysis. Scale bar: 
20 μm. (F) Principal component analysis (PCA) of three replicates of hiPSC-derived classical and subtype astrocytes based on the top 
500 genes with largest expression variance across samples. (G) Computational deconvolution of four major cell types in the human 
brain. Data is shown as mean ± SD. *Two-sample t-test: P < .05. (H) Volcano plot showing genes with differential expression (DE) in 
subtype astrocytes compared to classical astrocytes. The dotted line represents FDR <0.1. The five top genes with strongest association 
are labeled. (I) GO over-representation test of downregulated DE genes. The top 15 significant (FDR < 0.05) GO terms (biological 
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Fig. 2. Potential role of subtype astrocytes in SCZ. (A) Schematic illustration of the reprogramming and differentiation process of 
subtype astrocytes derived from HC and SCZ patients. Clozapine responders (R) and nonresponders (NR) are indicated. (B) All HC 
and SCZ hiPSCs expressed typical pluripotency markers. (C) All HC and SCZ hiPSCs stained positively for GFAP. (D) Intracellular 
glutamate levels (fold change) in SCZ subtype astrocytes relative to HC astrocytes. Measurements were performed in triplicates. Data 
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cellular processes related to glutamatergic processes. An 
important finding was a significant decrease in intracel-
lular glutamate concentrations in SCZ astrocytes which 
was likely driven by deficient glutamate synthesis rather 
than reduced uptake capacity. This is in line with our pre-
vious study showing no differences in glutamate uptake 
between hiPSC-derived SCZ and HC astrocytes.28 Several 
studies have reported excessive extracellular glutamate 
concentrations in SCZ patients, and this is thought to be 
a direct consequence of NMDA receptor hypofunction 
and reduced glutamate clearance by astrocytes.34 Our 
results suggest that de novo biosynthesis of  glutamate 
from glucose, which primarily takes place in astrocytes,34 
could act as a feedback mechanism by which increased 
levels of  synaptic glutamate are counterbalanced, and 
thus represent an important component of  glutamatergic 
regulation.34
Another important finding was a significant reduction 
in d-serine levels in SCZ astrocytes and a subsequent CLZ-
R-selective rescue induced by CLZ treatment. d-Serine is 
released by both astrocytes and neurons and binds to the 
glycine site of NMDA receptors to facilitate receptor ac-
tivation by glutamate. Decreased levels of d-serine have 
been reported in the cerebrospinal fluid (CSF) and blood 
of SCZ patients, and accumulating clinical evidence 
suggests that treatment with d-serine, especially in high 
doses, significantly improves positive, negative, and cog-
nitive symptoms in SCZ.35,36 Remarkably, CLZ response 
in our study was defined based on improvement in pos-
itive and negative symptoms, and CLZ treatment led to 
full recovery of d-serine in CLZ-R astrocytes only, pro-
viding further support for the positive effects of d-serine 
on these symptom groups. CLZ treatment has also been 
found to improve glial d-serine release in the rat cortex 
and in cultured astrocytes,37 but whether d-serine-related 
processes may act as mediators of clinical response has 
not been investigated. Our results suggest that the ther-
apeutic properties of CLZ may by be mediated by its 
ability to maintain a high d-serine pool and a consequent 
improvement in release capacity, indicating that the 
Fig. 3. Potential role of subtype astrocytes in CLZ response. (A) Fold change of d-serine levels (measured as the number of d-serine-
positive puncta) relative to HC1 before CLZ treatment. Left: Before CLZ treatment, Right: after CLZ treatment. The experiments were 
performed three times. Data shown as mean ± SD. Mann–Whitney U test: *P < .05 and **P < 0.01. (B) Expression levels of genes 
related to glutamate and d-serine metabolism and transport with nominally significant (P < .05) differences in CLZ-R vs. CLZ-NR 
samples. (C) PCA plots showing partial and complete clustering on CLZ response status across PCs 1–2 (left) and PCs 3–4 (right), 
respectively. The plots are based on the top 500 genes with largest expression variation across SCZ samples. (D) Global DE analysis 
between CLZ-R and CLZ-NR samples. Significant DE genes (FDR < 0.1) are labeled. (E) Heatmap of the four DE genes with 
differential expression in CLZ responders (R) compared to nonresponders (NR). Expression levels are shown as standardized z scores.
which RNA-seq data was available. The PCA analysis was based on the top 500 genes with largest expression variance. PC: principal 
component. (F) Computational deconvolution of human brain cell types in HC and SCZ samples. Data shown as mean ± SD. (G) 
Volcano plot showing significant DE genes (FDR < 0.1, dotted line). Top 5 genes with lowest P-values are labeled. (H) GO analysis of 
upregulated DE genes. Top 15 enriched (FDR < 0.05) GO terms (biological processes) are shown. (I) GO analysis of downregulated DE 
genes. Top 15 enriched (FDR < 0.05) GO terms are shown. (J) Top 15 disease terms of the CURATED DisGeNET database (10 370 
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regulation of d-serine biogenesis and metabolism may 
be exploited as a potential target for the development of 
novel therapeutic agents.
The systematic investigation of  astrocyte diversity is 
a nascent field of  astrocyte biology research which was 
partly motivated by the early detection of  morpholog-
ical heterogeneity between astrocytes.5,9 Researchers 
have since identified additional forms of  diversity, 
including cellular, regional, and functional, and are 
beginning to decipher their relevance in health and dis-
ease.8 Most of  these studies, however, have been carried 
out using rodent models, which may prove inadequate 
to recapitulate astrocyte diversity in humans as impor-
tant species differences exist.1,7 The main strength and 
novelty of  the present study was the use of  a human 
iPSC-derived cell model to explore the transcriptional 
mechanisms of  astrocyte diversity in the context of  SCZ 
and CLZ response. We identified distinct patterns of 
gene expression that differentiated this subpopulation 
from other astrocytes with a classical morphology, and 
found that subtype astrocytes from SCZ patients dis-
played a disease-specific expression signature, which 
indicates a potential role in SCZ pathology and may 
facilitate a more targeted approach towards pharma-
ceutical interventions.
Despite its strengths, however, our study also has lim-
itations which need to be addressed in subsequent work. 
First, the small sample size necessitates caution when 
interpreting the results as the reduced statistical power 
may be insufficient to disentangle the biological effects of 
interest from donor-specific variation. Second, additional 
functional analyses are needed to demonstrate that the 
cellular identity of the derived subtype astrocytes corres-
ponds to known subsets in the human brain.
In conclusion, our study represents a first attempt to 
investigate the potential role of astrocyte diversity in SCZ 
using human iPSCs derived from healthy individuals and 
SCZ patients. Our findings warrant additional investiga-
tions, in particular in-depth functional characterization 
of astrocyte populations, in order to further clarify the 
precise contribution of astrocytic heterogeneity to SCZ 
biology.
Supplementary Material
Supplementary material is available at Schizophrenia 
Bulletin online.
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